Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US medtech, biotech companies still concerned with revised patent reform bill - update

This article was originally published in RAJ Devices

Executive Summary

Legislation to reform US patent law has been revised and reintroduced in the House of Representatives and the Senate1,2. The Patent Reform Act of 2009 continues to draw stiff opposition from the medtech, biotech and pharmaceutical industry associations, despite attempts by lawmakers to address their concerns and make improvements to the previous version of the act that was introduced in the previous Congress.

You may also be interested in...



Inspection Interviews: Dutch Official Addresses Frustrations And Misconceptions

While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.

How Saudi Arabia Differs From The EU On Pharmacovigilance Inspections

The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.

EMA To Beef Up Guidance On Additional Risk Minimization Tools

Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel